PRF Technologies (PRFX) Cash from Investing Activities (2021 - 2024)
PRF Technologies (PRFX) posted quarterly Cash from Investing Activities of -$5000.0 for Q2 2024, up 99.5% year-on-year from -$2506.3 in Q3 2023, and up 28.57% on a QoQ basis from -$7000.0 in Q1 2024.
PRF Technologies (PRFX) Cash from Investing Activities (2021 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Cash from Investing Activities for 4 consecutive years, with -$5000.0 the latest figure, recorded in Q2 2024.
- Quarterly Cash from Investing Activities rose 99.5% year-over-year to -$5000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $979000.0 (up 197.61% YoY) and the FY2025 annual result came in at -$982000.0, down 7453.85% from the prior year.
- Cash from Investing Activities climbed to -$5000.0 in Q2 2024 per PRFX's latest filing, from -$7000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for PRFX reached as high as $22.0 million in Q4 2021 and fell as low as -$22.0 million in Q3 2021.
- A 4-year average of -$6166.7 and a median of -$6000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 3467.86% — and 2024, when it sank 100.12%.
- Year by year, Cash from Investing Activities stood at $22.0 million in 2021, then sank by 99.87% to $28000.0 in 2022, then surged by 3467.86% to $999000.0 in 2023, then sank by 100.5% to -$5000.0 in 2024.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$5000.0, -$7000.0, and $999000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.47 Bn | 30.53 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.10 Bn | 20.95 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -60.00 Mn |
| 10 | PRF Technologies | 732,209.49 | -3.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 999,000.00 |
| Dec 31, 2023 | 999,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Jun 30, 2023 | -1.00 Mn |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | 6.00 Mn |
| Mar 31, 2023 | 6.00 Mn |
| Dec 31, 2022 | 28,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | -6.03 Mn |
| Sep 30, 2022 | -6.03 Mn |
| Dec 31, 2021 | 21.95 Mn |
| Dec 31, 2021 | 21.95 Mn |
| Sep 30, 2021 | -21.98 Mn |
| Sep 30, 2021 | -21.98 Mn |